http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1016671-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41fca7e36d5554f3e37aa5bd5ddb5000 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
filingDate | 1991-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5209bbe07aa5d8d6d755940ac0dc21e6 |
publicationDate | 2000-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1016671-A2 |
titleOfInvention | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) |
abstract | A method for neutralizing HIV-1 is disclosed. Anpreferred embodiment utilizes a novel human monoclonalnantibody that binds to a conserved region of the gp41ntransmembrane subunit of the virus. The antibody isnproduced by continuous cell lines developed using human Bnlymphocyte cells collected from a patient possessing highntiters of anti-HIV antibodies. The conserved region boundnby the neutralizing antibody is a peptide of approximatelyn12 amino acids in length and preferably 8-10 amino acids.nSimilar regions on HIV-2 and SIV are also disclosed. Thenpresent invention is further directed to a kit and anmethod for detecting the presence and determiningnconcentration of an antibody that inhibits HIV-1n fusion-associated epitope , a peptide on gp41 with thenamino acid sequence represented by GCSGKLIC . Thendetection and quantitation method includes annenzyme-linked immunosorbent assay (ELISA). Thendetermination of the concentration of the antibody thatninhibits HIV-1 fusion-associated epitope on gp41, presentnin body fluids of a patient seropositive for HIV-1nantibodies, provides the physician with an objective meansnto form a prognosis for each individual case and assistsnthe clinician therefore in determining the appropriatenessnto initiate medical intervention or change therapy. |
priorityDate | 1990-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.